Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-14

Clinical Trial Update: Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of sarilumab in giant cell arteritis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sarilumab (sarilumab)

Snippet

Sponsor: Sanofi | Conditions: Giant Cell Arteritis | Phase 3 | Status: TERMINATED | Results posted: 2022-01-14